RegenxBio and Pfizer Partner on Gene Therapy for Friedreich's Ataxia

REGENXBIO, based in Rockville, Maryland, announced it entered a license deal with Pfizer for a gene therapy for Friedreich’s ataxia, the most common hereditary ataxia.

Under the terms of the deal, RegenxBio granted Pfizer a non-exclusive global license, with rights to sublicense, RegenxBio’s NAV AAV9 vector. In return, Pfizer is paying RegenxBio an upfront payment, various milestones and royalties on net sales. No financial details were disclosed.